Stock comparison
BioMarin Pharmaceutical
BMRN$11.44BHealthcare Market cap, Sector
Pro Medicus Limited
PME.AX$18.81BHealthcare Market cap, Sector
Overall winner
Pro Medicus Limited
BMRN 07 PME.AX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
BMRN0wins
7winsPME.AX
54D
B78
53D
A90
51D
A98
43F
A100
24F
B84
41F
A91
48D
A96
Side-by-side metrics
| Metric | BMRN | PME.AX |
|---|---|---|
| Market cap | $11.44B | $18.81B Winner |
| P/E (TTM) | Winner: 38.7x | 147.6x |
| EV/EBIT | Winner: 18.1x | 106.8x |
| ROIC (TTM) | 3.92% | 42.56% Winner |
| Gross margin | 75.93% | 99.85% Winner |
| Net margin | 8.29% | 54.12% Winner |
| Revenue CAGR 5y | 14.93% | 31.61% Winner |
| EPS CAGR 5y | Winner: 2.29% | 37.34% |
| Debt / Equity | 0.2x | 0.0x Winner |
| Dividend yield | 0.0% | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BMRN leads on
- EPS CAGR 5y2.29%vs 37.34%+84%
- EV/EBIT18.1xvs 106.8x+83%
- P/E (TTM)38.7xvs 147.6x+74%
PME.AX leads on
- Debt / Equity0.0xvs 0.2x+96%
- ROIC (TTM)42.56%vs 3.92%+91%
- Net margin54.12%vs 8.29%+85%
- Revenue CAGR 5y31.61%vs 14.93%+53%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.